Invention Grant
- Patent Title: FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
-
Application No.: US15999535Application Date: 2017-02-17
-
Publication No.: US11583528B2Publication Date: 2023-02-21
- Inventor: Lois Smith , Jean-Sebastien Joyal
- Applicant: Children's Medical Center Corporation
- Applicant Address: US MA Boston
- Assignee: Children's Medical Center Corporation
- Current Assignee: Children's Medical Center Corporation
- Current Assignee Address: US MA Boston
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/US2017/018418 WO 20170217
- International Announcement: WO2017/143220 WO 20170824
- Main IPC: A61K31/513
- IPC: A61K31/513 ; A61K31/352 ; A61K31/519 ; G01N33/50

Abstract:
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Public/Granted literature
- US20210322414A1 FFA1 (GPR40) AS A THERAPEUTIC TARGET FOR NEURAL ANGIOGENESIS DISEASES OR DISORDERS Public/Granted day:2021-10-21
Information query
IPC分类: